Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $103,581 | $70,265 | $66,578 | $103,223 |
| - Cash | $46,832 | $36,810 | $30,159 | $35,627 |
| + Debt | $3,598 | $30,101 | $29,000 | $29,702 |
| Enterprise Value | $60,347 | $63,556 | $65,419 | $97,298 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$44 |
| % Margin | – | – | – | – |
| EBITDA | -$25,383 | -$39,857 | -$27,728 | -$36,073 |
| % Margin | – | – | – | – |
| Net Income | -$26,451 | -$40,950 | -$28,796 | -$37,154 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.44 | -0.68 | -0.48 | -0.62 |
| % Growth | 35.3% | -41.7% | 22.6% | – |
| Operating Cash Flow | -$30,489 | -$31,832 | -$34,121 | -$27,215 |
| Capital Expenditures | $0 | -$9 | -$79 | $0 |
| Free Cash Flow | -$30,489 | -$31,841 | -$34,200 | -$27,215 |